Home  »  Hot Stocks   »  Pliant Therapeutics Inc. (PLRX) Reveals an Earning...

Pliant Therapeutics Inc. (PLRX) Reveals an Earnings Mystery

Pliant Therapeutics Inc. (NASDAQ:PLRX) went down by -8.80% from its latest closing price compared to the recent 1-year high of $24.81. The company’s stock price has collected -14.90% of loss in the last five trading sessions.

Is It Worth Investing in Pliant Therapeutics Inc. (NASDAQ :PLRX) Right Now?

Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for Pliant Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

The average price from analysts is $43.11, which is $22.49 above the current price. PLRX currently public float of 45.45M and currently shorts hold a 6.64% ratio of that float. Today, the average trading volume of PLRX was 2.05M shares.

PLRX’s Market Performance

PLRX stocks went down by -14.90% for the week, with a monthly jump of 8.70% and a quarterly performance of 163.68%, while its annual performance rate touched 15.97%. The volatility ratio for the week stands at 8.11% while the volatility levels for the past 30 days are set at 7.36% for Pliant Therapeutics Inc. The simple moving average for the period of the last 20 days is -2.21% for PLRX stocks with a simple moving average of 73.25% for the last 200 days.

Analysts’ Opinion of PLRX

Many brokerage firms have already submitted their reports for PLRX stocks, with Citigroup repeating the rating for PLRX by listing it as a “Buy.” The predicted price for PLRX in the upcoming period, according to Citigroup is $36 based on the research report published on September 01st of the current year 2022.

SVB Leerink, on the other hand, stated in their research note that they expect to see PLRX reach a price target of $33. The rating they have provided for PLRX stocks is “Outperform” according to the report published on July 20th, 2022.

Cantor Fitzgerald gave a rating of “Overweight” to PLRX, setting the target price at $28 in the report published on May 25th of the current year.

PLRX Trading at 3.55% from the 50-Day Moving Average

After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.89% of loss for the given period.

Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 8.11%, as shares surge +6.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.25% upper at present.

During the last 5 trading sessions, PLRX fell by -14.90%, which changed the moving average for the period of 200-days by +68.05% in comparison to the 20-day moving average, which settled at $21.15. In addition, Pliant Therapeutics Inc. saw 52.74% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PLRX starting from Coulie Bernard, who sale 12,502 shares at the price of $22.54 back on Sep 12. After this action, Coulie Bernard now owns 59,273 shares of Pliant Therapeutics Inc., valued at $281,851 using the latest closing price.

Coulie Bernard, the President and CEO of Pliant Therapeutics Inc., sale 12,498 shares at $22.50 during a trade that took place back on Jul 12, which means that Coulie Bernard is holding 59,273 shares at $281,205 based on the most recent closing price.

Stock Fundamentals for PLRX

Current profitability levels for the company are sitting at:

  • -1288.10 for the present operating margin
  • +57.69 for the gross margin

The net margin for Pliant Therapeutics Inc. stands at -1284.51. Equity return is now at value -59.00, with -52.20 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 12.44.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]